ISRCTN10334895进行中（未招募）2 期
CANnabidiol as a Treatment fOr clinical high-risk state Psychosis - a Randomised Clinical Trial (CANTOP-RCT)
King’s College London and South London and Maudsley NHS Foundation Trust0 个研究点目标入组 300 人开始时间: 2018年8月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18-35
- •2. Diagnosed with a clinical high-risk state for psychosis (CHR)
- •3. 'Attenuated psychotic symptoms' sub-group (CHR-APS) as defined using the CAARMS (Comprehensive Assessment of At-Risk Mental States) criteria
排除标准
- •1. History of a previous psychotic or manic episode lasting 7 days or more
- •2. Neurological disorders (e.g. epilepsy) or severe intercurrent illness
- •3. Current treatment with psychotropic medication or previous treatment with antipsychotic medication for more than 7 days
- •4. IQ of less than 70
- •5. Females who are pregnant, lactating or not using contraception
研究者
相似试验
进行中（未招募）
1 期
Cannabidiol as an add-on therapy in treatment-refractory psychotic disordersMedDRA version: 16.1Level: HLGTClassification code 10039628Term: Schizophrenia and other psychotic disordersSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2013-000240-26-GBKing's College London
尚未招募
2 期
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept StudyACTRN12614000248662SW5
招募中
1 期
Cannabidiol as an Adjunct for the Treatment of Anorexia Nervosa (CAFTAN): An Open Label Pilot Trial with Extension in Young PeopleMental Health - Eating disordersAnorexia nervosaACTRN12622001306707niversity of Sydney30
招募中
3 期
Cannabidiol for treatment of non-affective psychosis and cannabis use2024-517630-18-00Region Hovedstaden64
尚未招募
1 期
Efficacy and Safety of Low-dose Cannabidiol for anxietyAnxietyACTRN12623000803695PharmaCann Pty Ltd80